Funding for this research was provided by:
Japan Society for the Promotion of Science (JP16K09694, JP19H01045, JP19K07963, JP16H02657)
the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (JP 20ek019308h0003)
Received: 13 January 2021
Accepted: 19 May 2021
First Online: 5 June 2021
: All animal experiments were carried out according to the guidelines for the proper conduct of animal experiments published by the Science Council of Japan, and ethical approval for the study was granted by the animal care and use committee of Kyushu University (#No. A25-196).
: Not applicable.
: R.Y. has received honoraria from Teijin Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, Eisai, Novartis, Nihon Pharmaceutical, and CSL Behring; J.K. is a consultant for Biogen Japan and Medical Review, and has received honoraria from Bayer Healthcare, Mitsubishi Tanabe Pharma, Nobelpharma, Otsuka Pharmaceutical, Sanofi KK, Chugai Pharmaceutical Co. Ltd., Teijin Pharma, Novartis Pharma, and Medical Review; the remaining authors declare no conflicts of interest.